Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
View Patent ↗A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.
1. A method of treating non small cell lung cancer in a mammal, comprising administering to the mammal an effective amount of an compound, which is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and an effective amount of an EGFR inhibitor, wherein, the EGFR inhibitor is erlotinib and the effective amount of the compound and the effective amount of the EGFR inhibitor together results in a synergistic effect against the non-small cell lung cancer.
2. The method of claim 1 , wherein the subject is human.
3. The method of claim 1 , wherein the compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, or a tautomer or a pharmaceutically acceptable salt thereof.